WHAT WE CLAIM

1. An antibody molecule against dabigatran ~~comprising a heavy chain variable domain with a CDR1 selected from the group consisting of SEQ ID NO: 1, 7, 13, 19, 25, 31, 37, 43, 49, 55, 61, and 67, a CDR2 selected from the group consisting of SEQ ID NO: 2, 8, 14, 20, 26, 32, 38, 44, 50, 56, 62, and 68, and a CDR3 selected from the group consisting of SEQ ID NO: 3, 9, 15, 21, 27, 33, 39, 45, 51, 57, and 63, and a light chain variable domain with a CDR1 selected from the group consisting of SEQ ID NO: 4, 10, 16, 22, 28, 34, 40, 46, 52, 58, and 64, a CDR2 selected from the group consisting of SEQ ID NO: 5, 11, 17, 23, 29, 35, 41, 47, 53, 59, and 65, and a CDR3 selected from the group consisting of SEQ ID NO: 6, 12, 18, 24, 30, 36, 42, 48, 54, 60, 66, and 69.~~

~~2.~~ ~~The antibody molecule of claim 1~~ comprising a heavy chain variable domain with a CDR1 of SEQ ID NO: 1, a CDR2 of SEQ ID NO: 2, and a CDR3 of SEQ ID NO: 3, and a light chain variable domain with a CDR1 of SEQ ID NO: 4, a CDR2 of SEQ ID NO: 5, and a CDR3 of SEQ ID NO: 6.

~~3.~~2. ~~The~~ An antibody molecule against dabigatran ~~of claim 1~~ comprising a heavy chain variable domain with a CDR1 of SEQ ID NO: 7, a CDR2 of SEQ ID NO: 8, and a CDR3 of SEQ ID NO: 9, and a light chain variable domain with a CDR1 of SEQ ID NO: 10, a CDR2 of SEQ ID NO: 11, and a CDR3 of SEQ ID NO: 12.

~~4.~~3. ~~The~~ An antibody molecule against dabigatran ~~of claim 1~~ comprising a heavy chain variable domain with a CDR1 of SEQ ID NO: 13, a CDR2 of SEQ ID NO: 14, and a CDR3 of SEQ ID NO: 15, and a light chain variable domain with a CDR1 of SEQ ID NO: 16, a CDR2 of SEQ ID NO: 17, and a CDR3 of SEQ ID NO: 18.

~~5.~~4. ~~The~~ An antibody molecule against dabigatran ~~of claim 1~~ comprising a heavy chain variable domain with a CDR1 of SEQ ID NO: 19, a CDR2 of SEQ ID NO: 20, and a CDR3 of SEQ ID NO: 21, and a light chain variable domain with a CDR1 of SEQ ID NO: 22, a CDR2 of SEQ ID NO: 23, and a CDR3 of SEQ ID NO: 24.

6.5. The An antibody molecule against dabigatranof claim 1 comprising a heavy chain variable domain with a CDR1 of SEQ ID NO: 25, a CDR2 of SEQ ID NO: 26, and a CDR3 of SEQ ID NO: 27, and a light chain variable domain with a CDR1 of SEQ ID NO: 28, a CDR2 of SEQ ID NO: 29, and a CDR3 of SEQ ID NO: 30.

7.6. The An antibody molecule against dabigatranof claim 1 comprising a heavy chain variable domain with a CDR1 of SEQ ID NO: 31, a CDR2 of SEQ ID NO: 32, and a CDR3 of SEQ ID NO: 33, and a light chain variable domain with a CDR1 of SEQ ID NO: 34, a CDR2 of SEQ ID NO: 35, and a CDR3 of SEQ ID NO: 36.

8.7. The An antibody molecule against dabigatranof claim 1 comprising a heavy chain variable domain with a CDR1 of SEQ ID NO: 37, a CDR2 of SEQ ID NO: 38, and a CDR3 of SEQ ID NO: 39, and a light chain variable domain with a CDR1 of SEQ ID NO: 40, a CDR2 of SEQ ID NO: 41, and a CDR3 of SEQ ID NO: 42.

9.8. The An antibody molecule against dabigatranof claim 1 comprising a heavy chain variable domain with a CDR1 of SEQ ID NO: 43, a CDR2 of SEQ ID NO: 44, and a CDR3 of SEQ ID NO: 45, and a light chain variable domain with a CDR1 of SEQ ID NO: 46, a CDR2 of SEQ ID NO: 47, and a CDR3 of SEQ ID NO: 48.

10.9. The An antibody molecule against dabigatranof claim 1 comprising a heavy chain variable domain with a CDR1 of SEQ ID NO: 49, a CDR2 of SEQ ID NO: 50, and a CDR3 of SEQ ID NO: 51, and a light chain variable domain with a CDR1 of SEQ ID NO: 52, a CDR2 of SEQ ID NO: 53, and a CDR3 of SEQ ID NO: 54.

11.10. The An antibody molecule against dabigatran of claim 1 comprising a heavy chain variable domain with a CDR1 of SEQ ID NO: 55, a CDR2 of SEQ ID NO: 56, and a CDR3 of SEQ ID NO: 57, and a light chain variable domain with a CDR1 of SEQ ID NO: 58, a CDR2 of SEQ ID NO: 59, and a CDR3 of SEQ ID NO: 60.

12.11. The An antibody molecule against dabigatran of claim 1 comprising a heavy chain variable domain with a CDR1 of SEQ ID NO: 61, a CDR2 of SEQ ID NO: 62, and a CDR3 of SEQ ID NO: 63, and a light chain variable domain with a CDR1 of SEQ ID NO: 64, a CDR2 of SEQ ID NO: 65, and a CDR3 of SEQ ID NO: 66.

~~13.~~12. ~~The~~ An antibody molecule against dabigatran~~of claim 1~~ comprising a heavy chain variable domain with a CDR1 of SEQ ID NO: 67, a CDR2 of SEQ ID NO: 68, and a CDR3 of SEQ ID NO: 9, and a light chain variable domain with a CDR1 of SEQ ID NO: 64, a CDR2 of SEQ ID NO: 65, and a CDR3 of SEQ ID NO: 69.

~~14.~~13. The antibody molecule of claim 1 comprising a heavy chain variable domain of SEQ ID NO: 70, and a light chain variable domain of SEQ ID No: 71.

~~15.~~14. The antibody molecule of claim ~~1~~ 2 comprising a heavy chain variable domain of SEQ ID NO: 72, and a light chain variable domain of SEQ ID No: 73.

~~16.~~15. The antibody molecule of claim ~~1~~ 3 comprising a heavy chain variable domain of SEQ ID NO: 74, and a light chain variable domain of SEQ ID No: 75.

~~17.~~16. The antibody molecule of claim ~~1~~ 4 comprising a heavy chain variable domain of SEQ ID NO: 76, and a light chain variable domain of SEQ ID No: 77.

~~18.~~17. The antibody molecule of claim ~~1~~ 5 comprising a heavy chain variable domain of SEQ ID NO: 78, and a light chain variable domain of SEQ ID No: 79.

~~19.~~18. The antibody molecule of claim ~~1~~ 6 comprising a heavy chain variable domain of SEQ ID NO: 80, and a light chain variable domain of SEQ ID No: 81.

~~20.~~19. The antibody molecule of claim ~~1~~ 8 comprising a heavy chain variable domain of SEQ ID NO: 82, and a light chain variable domain of SEQ ID No: 83.

~~21.~~20. The antibody molecule of claim ~~1~~ 7 comprising a heavy chain variable domain of SEQ ID NO: 84, and a light chain variable domain of SEQ ID No: 85.

~~22.~~21. The antibody molecule of claim ~~1~~ 9 comprising a heavy chain variable domain of SEQ ID NO: 86, and a light chain variable domain of SEQ ID No: 87.

~~23.~~22. The antibody molecule of claim 10 comprising a heavy chain variable domain of SEQ ID NO: 88, and a light chain variable domain of SEQ ID No: 89.

~~24.~~23. The antibody molecule of claim 11 comprising a heavy chain variable domain of SEQ ID NO: 90, and a light chain variable domain of SEQ ID No: 91.

~~25.~~24. The antibody molecule of claim 12 comprising a heavy chain variable domain of SEQ ID NO: 92, and a light chain variable domain of SEQ ID NO: 93.

~~26.~~25. The antibody molecule of claim 12 comprising a heavy chain variable domain of SEQ ID NO: 92, and a light chain variable domain of SEQ ID NO: 94.

~~27.~~26. The antibody molecule of any one of claims 1 to ~~26~~25, wherein the light chain variable domain is fused to a constant domain of SEQ ID NO: 97.

~~28.~~27. The antibody molecule of any one of claims 1 to ~~25~~24, wherein the heavy chain variable domain is fused to a constant domain of SEQ ID NO: 98.

~~29.~~28. The antibody molecule of claim 1 comprising a heavy chain of SEQ ID NO: 95, and a light chain of SEQ ID No: 96.

~~30.~~29. The antibody molecule of claim 12 or 24 comprising a heavy chain of SEQ ID NO: 99, and a light chain of SEQ ID No: 100.

~~31.~~30. The antibody molecule of claim 12 or 25 comprising a heavy chain of SEQ ID NO: 99, and a light chain of SEQ ID No: 101.

~~32.~~31. The antibody molecule of any one of the preceding claims which is a polyclonal antibody, a monoclonal antibody, a human antibody, a humanized antibody, a chimeric antibody, a fragment of an antibody, in particular a Fab, Fab', or $F(ab')_2$ fragment, or a single chain antibody, in particular a single chain variable fragment (scFv)~~, a Small Modular Immunopharmaceutical (SMIP), a domain antibody, a nanobody, a diabody, or a Designed Ankyrin Repeat Protein (DARPin)~~.

~~33.~~32. The antibody molecule of any one of the preceding claims for use in medicine.

~~34.~~33. Antibody molecule of any one of the preceding claims for use in the therapy or prevention of side effects of anticoagulant therapy, and/or for reversal of an overdosing of an anticoagulant.

~~35.~~34. Antibody molecule of claim ~~34~~33, wherein the side effect is a bleeding event.

~~36.~~35. Method of manufacturing an antibody molecule of any one of the preceding claims, comprising

(a) providing a host cell comprising one or more nucleic acids encoding said antibody molecule in functional association with an expression control sequence,

(b) cultivating said host cell, and

(c) recovering the antibody molecule from the cell culture.

~~37.~~36. A kit comprising an antibody of any one of claims 1 to ~~32~~31, or a pharmaceutical composition thereof.

~~38.~~37. A kit comprising:

(a) an antibody of any one of claims 1 to ~~32~~31, or a pharmaceutical composition thereof;

(b) a container; and

(c) a label.

~~39. A kit comprising an antibody of any one of claims 1 to 32, and dabigatran, dabigatran etexilate, a prodrug of dabigatran or a pharmaceutically acceptable salt thereof.~~